These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22134373)

  • 61. Purinergic signaling in Parkinson's disease. Relevance for treatment.
    Navarro G; Borroto-Escuela DO; Fuxe K; Franco R
    Neuropharmacology; 2016 May; 104():161-8. PubMed ID: 26211977
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.
    Simola N; Morelli M; Pinna A
    Curr Pharm Des; 2008; 14(15):1475-89. PubMed ID: 18537671
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
    Petzer JP; Petzer A
    Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
    [TBL] [Abstract][Full Text] [Related]  

  • 66. How do adenosine A
    Mori A
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S13-S20. PubMed ID: 33349575
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
    Cacciari B; Spalluto G; Federico S
    Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
    Jenner P
    Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
    Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
    Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological assessments of potent A
    Kumari N; Agrawal S; Luthra PM
    Neurosci Lett; 2017 Apr; 647():53-60. PubMed ID: 28336342
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A(2A) adenosine receptors and Parkinson's disease severity.
    Casetta I; Vincenzi F; Bencivelli D; Corciulo C; Gentile M; Granieri E; Borea PA; Varani K
    Acta Neurol Scand; 2014 Apr; 129(4):276-81. PubMed ID: 24032478
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
    Paton DM
    Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adenosine A
    Waggan I; Rissanen E; Tuisku J; Joutsa J; Helin S; Parkkola R; Rinne JO; Airas L
    J Neurol; 2023 Jan; 270(1):300-310. PubMed ID: 36053386
    [TBL] [Abstract][Full Text] [Related]  

  • 74. How and why the adenosine A
    Jenner P; Kanda T; Mori A
    Int Rev Neurobiol; 2023; 170():73-104. PubMed ID: 37741697
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adenosine A(2A) receptors in Parkinson's disease treatment.
    Cieślak M; Komoszyński M; Wojtczak A
    Purinergic Signal; 2008 Dec; 4(4):305-12. PubMed ID: 18438720
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.
    Salamone JD
    IDrugs; 2010 Oct; 13(10):723-31. PubMed ID: 20878595
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease.
    Jorg M; Scammells PJ; Capuano B
    Curr Med Chem; 2014; 21(27):3188-210. PubMed ID: 24533801
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Pharmacological Potential of Adenosine A
    Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
    Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?].
    Jost WH; Tönges L
    Fortschr Neurol Psychiatr; 2022 Dec; 90(12):565-570. PubMed ID: 35226930
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
    Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
    Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.